Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05256797 · ClinicalTrials.gov registry record
Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 353,980
- Enrollment target
NCT05256797: Completed study, sponsored by Brigham and Women's Hospital.
NCT05256797 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 353,980 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05256797 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 353,980 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Claims-based algorithm: incidence of major bleeding or clinically relevant non-major bleeding events
Interventions
- DRUG Apixaban
- DRUG Rivaroxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353,980 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2022-06-15 |
What the finished NCT05256797 record still lists
NCT05256797 is an observational study that tracks outcomes without assigning an intervention. Its 353,980 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT05256797 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05256797 about?
NCT05256797 is a clinical study titled "Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT05256797?
This trial is currently completed. The enrollment target is 353,980 participants. The study started on 2021-05-03. Estimated completion is 2022-06-15.
What interventions are being tested in trial NCT05256797?
The interventions under investigation include: Apixaban (DRUG), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT05256797?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05668637 · 318,542 participants
Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support
- NCT06934239 · 400,000 participants · Phase 4
A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients
- NCT05365048 · 301,201 participants · NA
Provider Recommendation and HPV Vaccination
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI